BRP-187: A potent inhibitor of leukotriene biosynthesis that acts through impeding the dynamic 5-lipoxygenase/5-lipoxygenase-activating protein (FLAP) complex assembly


Garscha U., Voelker S., Pace S., Gerstmeier J., Emini B., Liening S., ...Daha Fazla

BIOCHEMICAL PHARMACOLOGY, cilt.119, ss.17-26, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 119
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1016/j.bcp.2016.08.023
  • Dergi Adı: BIOCHEMICAL PHARMACOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.17-26
  • Anahtar Kelimeler: 5-Lipoxygenase, 5-Lipoxygenase-activating protein, Leukotriene, Arachidonic acid, Inflammation, HUMAN POLYMORPHONUCLEAR LEUKOCYTES, ADJUVANT-INDUCED ARTHRITIS, 5-LIPOXYGENASE-ACTIVATING PROTEIN, IN-VIVO, MYOCARDIAL-INFARCTION, ARACHIDONIC-ACID, MEMBRANE-PROTEIN, PHARMACOLOGY, INFLAMMATION, GLUTATHIONE
  • Gazi Üniversitesi Adresli: Evet

Özet

The pro-inflammatory leukotrienes (LTs) are formed from arachidonic acid (AA) in activated leukocytes, where 5-lipoxygenase (5-LO) translocates to the nuclear envelope to assemble a functional complex with the integral nuclear membrane protein 5-LO-activating protein (FLAP). FLAP, a MAPEG family member, facilitates AA transfer to 5-LO for efficient conversion, and LT biosynthesis critically depends on FLAP. Here we show that the novel LT biosynthesis inhibitor BRP-187 prevents the 5-LO/FLAP interaction at the nuclear envelope of human leukocytes without blocking 5-LO nuclear redistribution. BRP-187 inhibited 5-LO product formation in human monocytes and polymorphonuclear leukocytes stimulated by lipopolysaccharide plus N-formyl-methionyl-leucyl-phenylalanine (IC50 = 7-10 nM), and upon activation by ionophore A23187 (IC50 = 10-60 nM). Excess of exogenous AA markedly impaired the potency of BRP-187. Direct 5-LO inhibition in cell-free assays was evident only at >35-fold higher concentrations, which was reversible and not improved under reducing conditions. BRP-187 prevented A23187-induced 5-LO/FLAP complex assembly in leukocytes but failed to block 5-LO nuclear translocation, features that were shared with the FLAP inhibitor MK886. Whereas AA release, cyclooxygenases and related LOs were unaffected, BRP-187 also potently inhibited microsomal prostaglandin E-2 synthase-1 (IC50 = 0.2 mu M), another MAPEG member. In vivo, BRP-187 (10 mg/kg) exhibited significant effectiveness in zymosan-induced murine peritonitis, suppressing LT levels in peritoneal exudates as well as vascular permeability and neutrophil infiltration. Together, BRP-187 potently inhibits LT biosynthesis in vitro and in vivo, which seemingly is caused by preventing the 5-LO/FLAP complex assembly and warrants further preclinical evaluation. (C) 2016 Elsevier Inc. All rights reserved.